HomeCirculationVol. 108, No. 13Platelets and Cardiovascular Disease Free AccessReview ArticlePDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessReview ArticlePDF/EPUBPlatelets and Cardiovascular Disease David Gregg, MD and Pascal J. Goldschmidt-Clermont, MD David GreggDavid Gregg From the Department of Medicine, Division of Cardiology, Duke University Medical Center, Durham, NC. Search for more papers by this author and Pascal J. Goldschmidt-ClermontPascal J. Goldschmidt-Clermont From the Department of Medicine, Division of Cardiology, Duke University Medical Center, Durham, NC. Search for more papers by this author Originally published30 Sep 2003https://doi.org/10.1161/01.CIR.0000086897.15588.4BCirculation. 2003;108:e88âe90Platelets are specialized disk-shaped cells in the blood stream that are involved in the formation of blood clots that play an important role in heart attacks, strokes, and peripheral vascular disease. In most people, the more than 200 million platelets in a milliliter of blood act as tiny building blocks to form the basis of a clot to stop bleeding from cuts or injuries. Platelets can detect a disruption in the lining of a blood vessel and react to build a wall to stop bleeding (Figure 1). Download figureDownload PowerPointFigure 1. Platelets form a platelet plug to stop bleeding from an injured blood vessel.In cardiovascular disease, abnormal clotting occurs that can result in heart attacks or stroke. Blood vessels injured by smoking, cholesterol, or high blood pressure develop cholesterol-rich build-ups (plaques) that line the blood vessel; these plaques can rupture and cause the platelets to form a clot. Even though no bleeding is occurring, platelets sense the plaque rupture and are confused, thinking that an injury has taken place that will cause bleeding. Instead of sealing the vessel to prevent bleeding as would occur with a cut, a clot forms in an intact blood vessel, causing a blockage of blood flow (Figure 2). Without blood, a portion of the heart muscle can die, leading to a heart attack. Download figureDownload PowerPointFigure 2. Plaque rupture results in clot formation to block blood flow, which may result in a heart attack or stroke.Platelet DisordersPlatelets may be abnormal either quantitatively (too many or too few) or qualitatively (the right number but they do not work correctly). The number of platelets is routinely tested as part of the complete blood count (CBC). Normal counts range from 150 000 to 450 000. A decrease in the number of platelets indicates a condition known as thrombocytopenia and may result in increased bleeding, the first signs of which may include gum bleeding, nose bleeds, and increased bruising. In cardiology, the most frequent cause of a low platelet count is an abnormal immune response caused by drug therapy, particularly with the intravenous blood thinner heparin (heparin-induced thrombocytopenia), and rarely with other drugs to control high blood pressure or symptoms of congestive heart failure (diuretics), to control diabetes (antidiabetic medications), or to regulate your blood clotting (antiplatelet drugs). Elevated platelet counts can also occur, usually in association with diseases in the elderly, and can result in either excess clotting or even abnormal bleeding.Platelet DysfunctionBecause platelets are so important in stopping bleeding from everyday injuries such as cuts or bruises, severe inherited disorders of platelets are quite rare. Researchers, however, have discovered more subtle genetic variations in platelets called polymorphisms that may alter platelets in subtle ways to raise the risk of cardiovascular disease when combined with other risk factors, but which on their own do not result in overt disease. These polymorphisms may also be important in understanding who may gain the greatest benefit from drugs such as aspirin that alter platelet function. Because abnormal clots cause heart attack, your doctor can prescribe drugs (antiplatelet agents) to inhibit clot formation and reduce the risk of cardiovascular disease.Antiplatelet AgentsThe most commonly used antiplatelet agent is aspirin, although you may also be prescribed other oral agents, such as ticlopidine, clopidogrel, or dipyridamole, or intravenous antiplatelet drugs such as abciximab or eptifibatide while you are in the hospital or undergoing angioplasty procedures. Each agent affects platelets in slightly different ways and may have unique side effects, but all either cause the platelets to stick together or induce them to clot less well. Your doctor will choose the drug that best suits your situation. Table 1 shows some of the unique features of commonly used oral antiplatelet drugs. TABLE 1. Commonly Used Oral Antiplatelet Drugs: Uses and Side EffectsAspirinClopidogrelTiclopidineDipyridamole + AspirinUsesHeart disease and stroke; inexpensiveHeart disease and stroke, particularly after stentingMostly in stroke; requires blood count monitoringStroke; may not be suitable for patients with heart diseaseSide effectsGastrointestinal (GI) intolerance; GI bleedingDiarrhea (much less common than with ticlopidine); rash and itchingDiarrhea and GI upset (usually resolves in 2 weeks); may decrease blood counts, particularly white blood cellsHeadache; GI bleeding; GI intoleranceAntiplatelet drugs are different than blood thinners or anticoagulants such as warfarin (Coumadin, Bristol-Myers Squibb) or heparin. Anticoagulants block a second step in clotting known as coagulation but do not directly affect the platelets. If you are taking an anticoagulant, you should discuss with your doctor whether it is proper for you to take an antiplatelet drug such as aspirin.When Are Antiplatelet Agents Used?Antiplatelet agents are used to treat many common cardiovascular problems. Your doctor may recommend aspirin to prevent a heart attack if you have risk factors for heart disease. Both aspirin and more powerful intravenous antiplatelet agents may be used if you are having uncontrolled chest pain or a heart attack. Other common uses are listed in Table 2. TABLE 2. Uses for Antiplatelet AgentsPrevention of heart diseaseDuring heart attackProgressive chest pain (unstable angina)After a heart attackDuring or after angioplasty and stentingPrevention of stroke or TIAAtrial fibrillation (low risk patients)Peripheral vascular diseaseWhat Do Antiplatelet Drugs Do?By limiting the ability of platelets to clot, antiplatelet drugs help to prevent clot formation that can block blood vessels and lead to heart attack or stroke. In high-risk patients, aspirin decreases the risk of first time heart attack by more than 20%. After a heart attack, aspirin can reduce the risk of a recurrent heart attack by about 30%. Similarly, an antiplatelet agent can reduce the risk of recurrent stroke or transient ischemic attack and help to prevent the blockage (occlusion) of vessels that have previously been opened (patency) with a stent.How Are Antiplatelet Drugs Monitored?Unlike anticoagulants such as warfarin or heparin, antiplatelet therapy generally does not require blood test monitoring. Researchers are working to develop tests that may more easily test platelet function and an individualâs response to antiplatelet agents to better predict what drug works best with the fewest side effects for a unique patient. These tests, however, are not yet widely available.Summary: What to Watch forThe most significant side-effect of antiplatelet therapy is that it may increase bleedingSigns of abnormal platelet function may include Black or bloody stools Pink or bloody urine Increased menstrual bleeding Bleeding gums Nose BleedsDo not take aspirin with anticoagulants unless instructed by your doctorAvoid over the counter pain medicines (NSAIDS) except Tylenol. Use of these pain medicines can increase your risk of stomach bleeding and may, particularly with ibuprofen (Advil), limit the benefit of aspirin in cardiovascular prevention.Be aware that cold medicines, back ache remedies, and other medicines may contain aspirin or ibuprofen.Tell your doctor or dentist before surgical or dental procedures that you are taking an antiplatelet drug.FootnotesCorrespondence to Pascal J. Goldschmidt-Clermont, MD, Division of Cardiology, Duke University Medical Center, Durham, NC 27710. E-mail [email protected]Additional Resources1 American Heart Association. Heart and stroke facts. Available at: http://www.americanheart.org/downloadable/heart/10148338654401013191236985HSfacts02.pdf. Accessed August 27, 2003.Google Scholar2 Medem, Inc. Medical library: heart disease/stroke/coronary artery disease and heart attack. Available at: http://www.medem.com/MedLB/articleslb.cfm?sub_cat=272. Accessed August 27, 2003.Google Scholar Previous Back to top Next FiguresReferencesRelatedDetailsCited By Mandloi S, Ujjaliya N and Jain P (2022) Experimental antithrombotic effect of medicinal plants: A critical review, INDIAN JOURNAL OF AYURVEDA & INTEGRATIVE MEDICINE KLEU, 10.4103/ijaim.ijaim_9_22, 3:1, (12), . Zhang J, Yuan T, Wei S, Feng Z, Li B and Huang H (2022) New strategy for clinical etiologic diagnosis of acute ischemic stroke and blood biomarker discovery based on machine learning, RSC Advances, 10.1039/D2RA02022J, 12:23, (14716-14723) Liu H, Zang C, Yuan F, Ju C, Shang M, Ning J, Yang Y, Ma J, Li G, Bao X and Zhang D (2022) The role of FUNDC1 in mitophagy, mitochondrial dynamics and human diseases, Biochemical Pharmacology, 10.1016/j.bcp.2021.114891, 197, (114891), Online publication date: 1-Mar-2022. Lemos da Silva L, de Athayde A, Moreira M, Tizziani T, Gkionis S, da Silva L, Biavatti M, de Moraes A, dos Santos Nascimento M, Dalmarco E and Sandjo L (2022) Antiâinflammatory and antiâaggregating effects of rangpur in the first trimester of growth: ultraâperformance liquid chromatographyâelectrospray mass spectrometry profile and quantification of hesperidin, Journal of the Science of Food and Agriculture, 10.1002/jsfa.11764, 102:10, (4151-4161), Online publication date: 15-Aug-2022. Lim S, Selvaraji S, Lau H and Li S (2022) Application of omics beyond the central dogma in coronary heart disease research: A bibliometric study and literature review, Computers in Biology and Medicine, 10.1016/j.compbiomed.2021.105069, 140, (105069), Online publication date: 1-Jan-2022. Jain K, Tyagi T, Du J, Hu X, Patell K, Martin K and Hwa J (2022) Unfolded Protein Response Differentially Modulates the Platelet Phenotype, Circulation Research, 131:4, (290-307), Online publication date: 5-Aug-2022. Baumer Y, Gutierrez-Huerta C, Saxena A, Dagur P, Langerman S, Tamura K, Ceasar J, Andrews M, Mitchell V, Collins B, Yu Q, Teague H, Playford M, Bleck C, Mehta N, McCoy J and Powell-Wiley T (2020) Immune cell phenotyping in low blood volumes for assessment of cardiovascular disease risk, development, and progression: a pilot study, Journal of Translational Medicine, 10.1186/s12967-020-02207-0, 18:1, Online publication date: 1-Dec-2020. Harshfield E, Sims M, Traylor M, Ouwehand W and Markus H (2019) The role of haematological traits in risk of ischaemic stroke and its subtypes, Brain, 10.1093/brain/awz362, 143:1, (210-221), Online publication date: 1-Jan-2020. AlarcĂłn M (2019) Generation of platelet-derived microparticles through the activation of the toll-like receptor 4, Heliyon, 10.1016/j.heliyon.2019.e01486, 5:4, (e01486), Online publication date: 1-Apr-2019. He S, Lei W, Li J, Yu K, Yu Y, Zhou L, Zhang X, He M, Guo H, Yang H and Wu T (2019) Relation of Platelet Parameters With Incident Cardiovascular Disease (The Dongfeng-Tongji Cohort Study), The American Journal of Cardiology, 10.1016/j.amjcard.2018.10.016, 123:2, (239-248), Online publication date: 1-Jan-2019. Gill D, Monori G, Georgakis M, Tzoulaki I and Laffan M (2018) Genetically Determined Platelet Count and Risk of Cardiovascular Disease, Arteriosclerosis, Thrombosis, and Vascular Biology, 38:12, (2862-2869), Online publication date: 1-Dec-2018. Lassale C, Curtis A, Abete I, van der Schouw Y, Verschuren W, Lu Y and Bueno-de-Mesquita H (2018) Elements of the complete blood count associated with cardiovascular disease incidence: Findings from the EPIC-NL cohort study, Scientific Reports, 10.1038/s41598-018-21661-x, 8:1, Online publication date: 1-Dec-2018. Carter C (2018) Alterations in Blood Components Comprehensive Toxicology, 10.1016/B978-0-12-801238-3.64251-4, (249-293), . (2018) Epidemiology of Cardiovascular Disease Nutraceuticals and Human Blood Platelet Function, 10.1002/9781119375913.ch2, (29-45) Li X, Wang Q, Xue Y, Chen J and Lv Q (2017) Ticagrelor Compared with Clopidogrel Increased Adenosine and Cyclic Adenosine Monophosphate Plasma Concentration in Acute Coronary Syndrome Patients, Basic & Clinical Pharmacology & Toxicology, 10.1111/bcpt.12752, 120:6, (610-614), Online publication date: 1-Jun-2017. Meinshausen M, Rieckert A, Renom-Guiteras A, Kröger M, Sommerauer C, Kunnamo I, Martinez Y, Esmail A and Sönnichsen A (2017) Effectiveness and patient safety of platelet aggregation inhibitors in the prevention of cardiovascular disease and ischemic stroke in older adults â a systematic review, BMC Geriatrics, 10.1186/s12877-017-0572-7, 17:S1, Online publication date: 1-Oct-2017. Graham B, Darabos C, Huang M, Muglia L, Moore J and Williams S (2017) Evolutionarily derived networks to inform disease pathways, Genetic Epidemiology, 10.1002/gepi.22078, 41:8, (866-875), Online publication date: 1-Dec-2017. Fang K, Cheng Y, Su C, Wang Y, Lan K, Huo T, Huang Y, Chu C, Lin C, Hou M, Lin H, Lee F, Wu J and Lee S (2017) Higher platelet counts are associated with metabolic syndrome independent of fatty liver diagnosis, Journal of the Chinese Medical Association, 10.1016/j.jcma.2016.07.003, 80:3, (125-132), Online publication date: 1-Mar-2017. Lu D, Hsu C, Huang S, Tu H, Huang T, Liou H, Liao H, Chen C, Fu W and Gau S (2017) ARHGEF10 knockout inhibits platelet aggregation and protects mice from thrombus formation , Journal of Thrombosis and Haemostasis, 10.1111/jth.13799, 15:10, (2053-2064), Online publication date: 1-Oct-2017. Bader K, Bouchoux G and Holland C (2016) Sonothrombolysis Therapeutic Ultrasound, 10.1007/978-3-319-22536-4_19, (339-362), . Wong W, Ismail M, Tohit E, Abdullah R and Zhang Y (2016) Attenuation of Thrombosis by Crude Rice ( Oryza sativa ) Bran Policosanol Extract: Ex Vivo Platelet Aggregation and Serum Levels of Arachidonic Acid Metabolites , Evidence-Based Complementary and Alternative Medicine, 10.1155/2016/7343942, 2016, (1-8), . Molaison L, Ojala O, Warren S, McIntyre C and Taylor C (2016) Characterization of a Shear Thinning Fluid System for Cardiovascular Medical Device Assessment 2016 32nd Southern Biomedical Engineering Conference (SBEC), 10.1109/SBEC.2016.89, 978-1-5090-2132-1, (122-123) Izquierdo I and GarcĂa Ă (2016) Platelet proteomics applied to the search for novel antiplatelet therapeutic targets, Expert Review of Proteomics, 10.1080/14789450.2016.1246188, 13:11, (993-1006), Online publication date: 1-Nov-2016. Xie Y, Zhang J, Liu W, Xie N, Feng F and Qu W (2016) New urushiols with platelet aggregation inhibitory activities from resin of Toxicodendron vernicifluum, Fitoterapia, 10.1016/j.fitote.2016.05.001, 112, (38-44), Online publication date: 1-Jul-2016. Derosa G and Maffioli P (2016) Testing Pharmacological Profiles with Biomarkers Relevant to Cardiovascular Profiles Biomarkers in Cardiovascular Disease, 10.1007/978-94-007-7678-4_27, (3-26), . Lee C and Ayob Y (2015) Approach to managing platelet refractory patients, ISBT Science Series, 10.1111/voxs.12139, 10:S1, (89-94), Online publication date: 1-Apr-2015. Yazigi Junior J, Gomes dos Santos J, Xavier B, Fernandes M, Valente S and Leite V (2015) Quantificação do nĂșmero de plaquetas a partir de diferentes mĂ©todos de centrifugação em ratos da linhagem SHR, Revista Brasileira de Ortopedia, 10.1016/j.rbo.2015.04.018, 50:6, (729-738), Online publication date: 1-Nov-2015. Baccarelli A and Byun H (2015) Platelet mitochondrial DNA methylation: a potential new marker of cardiovascular disease, Clinical Epigenetics, 10.1186/s13148-015-0078-0, 7:1, Online publication date: 1-Dec-2015. AlarcĂłn M, Fuentes E, Olate N, Navarrete S, Carrasco G and Palomo I (2014) Strawberry extract presents antiplatelet activity by inhibition of inflammatory mediator of atherosclerosis (sP-selectin, sCD40L, RANTES, and IL-1ÎČ) and thrombus formation, Platelets, 10.3109/09537104.2014.898747, 26:3, (224-229), Online publication date: 3-Apr-2015. Fuentes E, Palomo I and AlarcĂłn M (2015) Platelet miRNAs and cardiovascular diseases, Life Sciences, 10.1016/j.lfs.2015.04.016, 133, (29-44), Online publication date: 1-Jul-2015. Derosa G and Maffioli P (2015) Testing Pharmacological Profiles with Biomarkers Relevant to Cardiovascular Profiles Biomarkers in Cardiovascular Disease, 10.1007/978-94-007-7741-5_27-1, (1-24), . Burkhart J and Wolf T (2015) Krankhafte VerĂ€nderungen im Blut detektieren, Nachrichten aus der Chemie, 10.1002/nadc.201590323, 63:10, (1011-1013), Online publication date: 1-Oct-2015. Fuentes E and Palomo I (2015) Extracellular ATP metabolism on vascular endothelial cells: A pathway with pro-thrombotic and anti-thrombotic molecules, Vascular Pharmacology, 10.1016/j.vph.2015.05.002, 75, (1-6), Online publication date: 1-Dec-2015. Yazigi Junior J, dos Santos J, Xavier B, Fernandes M, Valente S and Leite V (2015) Quantification of platelets obtained by different centrifugation protocols in SHR rats, Revista Brasileira de Ortopedia (English Edition), 10.1016/j.rboe.2015.10.008, 50:6, (729-738), Online publication date: 1-Nov-2015. Burkhart J, Gambaryan S, Watson S, Jurk K, Walter U, Sickmann A, Heemskerk J and Zahedi R (2014) What Can Proteomics Tell Us About Platelets?, Circulation Research, 114:7, (1204-1219), Online publication date: 28-Mar-2014. Thushara R, Hemshekhar M, Paul M, Shanmuga Sundaram M, Shankar R, Kemparaju K and Girish K (2014) Crocin prevents sesamol-induced oxidative stress and apoptosis in human platelets, Journal of Thrombosis and Thrombolysis, 10.1007/s11239-014-1056-7, 38:3, (321-330), Online publication date: 1-Oct-2014. Sharma A, Astekar M, Metgud R, Soni A, Verma M and Patel S (2014) A study of C-reactive protein, lipid metabolism and peripheral blood to identify a link between periodontitis and cardiovascular disease, Biotechnic & Histochemistry, 10.3109/10520295.2014.918280, 89:8, (577-582), Online publication date: 1-Nov-2014. Fuentes E and Palomo I (2014) Regulatory mechanisms of cAMP levels as a multiple target for antiplatelet activity and less bleeding risk, Thrombosis Research, 10.1016/j.thromres.2014.04.027, 134:2, (221-226), Online publication date: 1-Aug-2014. Fuentes E, Pereira J, AlarcĂłn M, Valenzuela C, PĂ©rez P, Astudillo L and Palomo I (2013) Protective Mechanisms of S. lycopersicum Aqueous Fraction (Nucleosides and Flavonoids) on Platelet Activation and Thrombus Formation: In Vitro , Ex Vivo and In Vivo Studies , Evidence-Based Complementary and Alternative Medicine, 10.1155/2013/609714, 2013, (1-13), . Wieschhaus A, Le Breton G and Chishti A (2012) Headpiece Domain of Dematin Regulates Calcium Mobilization and Signaling in Platelets, Journal of Biological Chemistry, 10.1074/jbc.M112.364679, 287:49, (41218-41231), Online publication date: 1-Nov-2012. Vega C and Kwik-Uribe C (2012) Theobroma cacaoâAn Introduction to the Plant, Its Composition, Uses, and Health Benefits Cocoa Butter and Related Compounds, 10.1016/B978-0-9830791-2-5.50005-0, (35-62), . Liu F, Liao C, Chang Y, Liou J and Day Y (2009) Splitomicin suppresses human platelet aggregation via inhibition of cyclic AMP phosphodiesterase and intracellular Ca++ release, Thrombosis Research, 10.1016/j.thromres.2009.02.013, 124:2, (199-207), Online publication date: 1-Jun-2009. Bertin A, Mahaney M, Cox L, Rogers J, VandeBerg J, Brugnara C and Platt O (2007) Quantitative trait loci for peripheral blood cell counts: a study in baboons, Mammalian Genome, 10.1007/s00335-007-9022-8, 18:5, (361-372), Online publication date: 24-Jul-2007. Dunleavy M, Dooley M, Cox D and Bradford A (2005) Chronic intermittent asphyxia increases platelet reactivity in rats, Experimental Physiology, 10.1113/expphysiol.2004.029306, 90:3, (411-416), Online publication date: 1-May-2005. Braune S, KĂŒpper J and Jung F (2020) Effect of Prostanoids on Human Platelet Function: An Overview, International Journal of Molecular Sciences, 10.3390/ijms21239020, 21:23, (9020) Fuentes E, Wehinger S and Trostchansky A (2021) Regulation of Key Antiplatelet Pathways by Bioactive Compounds with Minimal Bleeding Risk, International Journal of Molecular Sciences, 10.3390/ijms222212380, 22:22, (12380) Chiu P, Chattopadhyay A, Wu M, Hsiao T, Lin C and Lu T (2021) Elucidation of a Causal Relationship Between Platelet Count and Hypertension: A Bi-Directional Mendelian Randomization Study, Frontiers in Cardiovascular Medicine, 10.3389/fcvm.2021.743075, 8 Zhu C, Ma J, Ji Z, Shen J and Wang Q (2021) Recent Advances of Cell Membrane Coated Nanoparticles in Treating Cardiovascular Disorders, Molecules, 10.3390/molecules26113428, 26:11, (3428) Geraldo R, Sathler P, Lourenço A, Saito M, Cabral L, Rampelotto P and Castro H (2014) Platelets: Still a Therapeutical Target for Haemostatic Disorders, International Journal of Molecular Sciences, 10.3390/ijms151017901, 15:10, (17901-17919) Alfatni A, Riou M, Charles A, Meyer A, Barnig C, Andres E, Lejay A, Talha S and Geny B (2020) Peripheral Blood Mononuclear Cells and Platelets Mitochondrial Dysfunction, Oxidative Stress, and Circulating mtDNA in Cardiovascular Diseases, Journal of Clinical Medicine, 10.3390/jcm9020311, 9:2, (311) Andrade S, Faria A, GirĂŁo M, Fuhler G, Peppelenbosch M and Ferreira-Halder C (2020) Biotech-Educated Platelets: Beyond Tissue Regeneration 2.0, International Journal of Molecular Sciences, 10.3390/ijms21176061, 21:17, (6061) Das Roy P, Sengupta D, Dasgupta A, Kundu S, Chaudhuri U, Thakur I, Guha P, Majumder M, Roy R, Roy B and Xiong M (2013) Single Nucleotide Polymorphism Network: A Combinatorial Paradigm for Risk Prediction, PLoS ONE, 10.1371/journal.pone.0074067, 8:9, (e74067) September 30, 2003Vol 108, Issue 13 Advertisement Article InformationMetrics https://doi.org/10.1161/01.CIR.0000086897.15588.4BPMID: 14517153 Originally publishedSeptember 30, 2003 PDF download Advertisement